IQ 50 Percent Hedged FTSE International ETF
HFXI - ETF AI Analysis
Top Page
IQ 50 Percent Hedged FTSE International ETF (HFXI)
HFXI’s rating suggests it is a solid but not top-tier international ETF, with its quality driven largely by strong holdings in companies like Novartis, HSBC, and AstraZeneca, which show robust financial performance, positive earnings outlooks, and supportive technical trends. Additional support comes from names like ASML, Roche, Shell, Nestlé, and Mitsubishi UFJ, though some face valuation concerns, potential overbought conditions, or cash flow and leverage risks that slightly weigh on the fund’s overall appeal. The main risk factor is its exposure to several large, globally diversified firms where high valuations and sector-specific challenges (especially in healthcare and financials) could increase volatility.
HFXI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 2.55B
- Region
- Developed Markets
- Expense Ratio
- 0.20%
- Beta
- 0.80
- Issuer
- NYLIM
- Inception Date
- Jul 22, 2015
- Dividend Yield
- 3.19%
- Asset Class
- Equity
- Index Tracked
- FTSE Developed ex North America 50% Hedged to USD Index
HFXI Summary
HFXI is an exchange-traded fund that follows the FTSE Developed ex North America 50% Hedged to USD Index, giving you broad exposure to stocks from developed countries outside the U.S. and Canada, with half of the currency risk reduced. It owns many well-known international companies such as Samsung Electronics, Nestlé, and Shell, across sectors like technology, finance, and health care. Someone might invest in HFXI to diversify beyond the U.S. market while still limiting some of the impact of foreign currency swings. A key risk is that international stock prices can still go up and down significantly with global markets.
How much will it cost me?
HFXI has an expense ratio of 0.20%, which means you’ll pay about $2 per year for every $1,000 invested. This cost is slightly higher than the cheapest index ETFs because it uses a partial currency hedge and a more specialized strategy, but it’s still relatively low compared with many actively managed funds.
What would affect this ETF?
HFXI could benefit if developed markets outside North America grow steadily, especially in technology, financials, and health care, and if currency swings remain moderate so its 50% hedge helps smooth returns without losing too much upside. On the downside, global slowdowns, banking or energy sector stress, stricter regulations in key countries, or sharp moves in foreign currencies against the U.S. dollar could hurt performance even with partial currency protection.
HFXI Top 10 Holdings
HFXI leans heavily on global blue chips, with a clear tilt toward overseas tech and healthcare leaders. Samsung Electronics is a steady anchor, while SK hynix and ASML have been more mixed lately, occasionally losing steam and dampening the fund’s momentum despite their long-term semiconductor appeal. On the brighter side, defensive names like Nestlé and pharma giants Novartis and AstraZeneca are quietly rising, helping smooth out volatility. Financials such as HSBC and Mitsubishi UFJ are more of a mixed bag, leaving performance driven largely by non-U.S. Europe and Asia stalwarts.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Samsung Electronics | 2.83% | $70.62M | KRW 1315.56T | 100.39% | ―― | |
| ASML Holding NV | 2.33% | $58.16M | EUR 536.23B | 51.88% | 76Outperform | |
| SK hynix Inc. | 2.14% | $53.33M | KRW 930.76T | 103.24% | ―― | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Novartis AG | 1.15% | $28.77M | CHF 242.99B | 26.78% | 80Outperform | |
| HSBC Holdings | 1.20% | $29.91M | GBP 232.19B | 20.93% | 80Outperform | |
| Shell (UK) | 1.11% | $27.59M | GBP 207.92B | 30.08% | 73Outperform | |
| AstraZeneca | ― | ― | ― | ― | 80Outperform | |
| Nestlé SA | 1.02% | $25.48M | CHF 220.98B | 8.18% | 71Outperform | |
| SAP SE | 0.90% | $22.46M | EUR 246.30B | -2.13% | 66Neutral |
HFXI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HFXI, the sentiment is Positive. The current price of 36.61 is above the 20-day moving average (MA) of 36.40, below the 50-day MA of 36.99, and above the 200-day MA of 36.32, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 49.48 is Neutral, neither overbought nor oversold. The STOCH value of 70.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HFXI.
HFXI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $36.61 | $39.00(6.53% Upside) | $2.55B | 0.20% | 60Neutral | |
| $56.04 | $66.13(18.01% Upside) | $9.51B | 0.35% | 65Neutral | |
| $78.10 | $92.61(18.58% Upside) | $6.59B | 0.07% | 66Neutral | |
| $96.91 | $102.08(5.34% Upside) | $5.63B | 0.20% | 61Neutral | |
| $53.10 | $63.26(19.14% Upside) | $2.11B | 0.58% | 66Neutral | |
| $46.50 | $53.26(14.54% Upside) | $1.45B | 0.40% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HFXI | IQ 50 Percent Hedged FTSE International ETF | 36.61 | 5.84 | 18.98% | |
| DBEF | Xtrackers MSCI EAFE Hedged Equity ETF | 56.04 | 9.47 | 20.33% | |
| BBIN | JPMorgan BetaBuilders International Equity ETF | 78.10 | 9.98 | 14.66% | |
| EFAV | iShares MSCI EAFE Min Vol Factor ETF | 96.91 | 14.12 | 17.05% | |
| IHDG | WisdomTree International Hedged Quality Dividend Growth Fund | 53.10 | 7.05 | 15.30% | |
| DDWM | WisdomTree Dynamic Currency Hedged International Equity Fund | 46.50 | 5.52 | 13.48% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
